Skip to content
StockMarketAgent
Direct answer
HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $497, high $798, with mid-point at $647.
Stock analysis

HCA HCA fair value $497–$798

HCA
By StockMarketAgent.AI team· supervised by
Analysiert: 2026-05-13Nächste Aktualisierung: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Kurs
$426.37
▲ +220.89 (+51.81%)
Fair Value
$647
$497–$798
Rating
Starker Kauf
confidence 88/100
Aufwärtspotenzial
+51.8%
upside to fair value
Sicherheitsmarge
$550.17
MoS level · 15%
Marktkapitalisierung
$94.6B
P/E fwd 12.9
Englische QuelleDE
Englische Quelle wird angezeigt, während wir übersetzen
Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.

§1 Zusammenfassung

  • Composite fair value $647 with high case $798.
  • Implied upside of 51.8% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$647
Margin of safety
+34.1%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$426.37Price
Low $496.77
Mid $647.26
High $798.49

HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Local market density and scale
    Local market density and scale advantages driving industry-leading margins.
  • Demographic tailwinds with an aging
    Demographic tailwinds with an aging population ensuring consistent volume.
  • Bull thesis
    Market under-appreciates the durability of HCA's local market density and the resultant ROIC/WACC spread.

§2 Bärenszenario

A prolonged period of elevated interest rates combined with flat commercial volumes and margin compression to 13% would severely stress HCA's free cash flowFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics., threatening the heavily leveraged capital structure and ending the share repurchase algorithm.

Wie diese These scheitern kann

Severe Reimbursement Cuts

· Medium

Government payers drastically compress Medicare/Medicaid rates to manage ballooning deficits, crushing margins.

FV impact
Downside anchoring near Expected Value of $421
Trigger
12 to 24 months

Structural Labor Shortage

· High

Persistent clinical staff shortages force a permanent reliance on expensive contract labor, eroding operating margins below 14%.

FV impact
Valuation anchors to Forward Earnings mid $420
Trigger
6 to 18 months

Debt Cost Spiral

· Low

Refinancing the massive $48.7B net debt load at significantly higher rates extinguishes the aggressive buyback program.

FV impact
Severe reduction in Owner Earnings fair value and DCF upside
Trigger
24 to 36 months
Frühwarnsignale zur Überwachung
KennzahlAktuellAuslöseschwelle
Operating margin falling below 14.0% in consecutive quarters.MonitorDeterioration versus the report thesis
Year-over-year reduction in diluted shares outstanding falling below 3%.MonitorDeterioration versus the report thesis
Sustained acceleration in contract labor costs.MonitorDeterioration versus the report thesis
Negative shift in payer mix toward government and uninsured.MonitorDeterioration versus the report thesis
Deterioration of free cash flow conversion below $7B annually.MonitorDeterioration versus the report thesis

§3 Finanzielle Historie

Gewinn- und Verlustrechnung — letzte sechs Perioden
PositionT−0T−1T−2T−3T−4CAGR
Periode2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
Umsatz—$60.23B$64.97B$70.60B$75.60B+5.8%
Bruttogewinn—$23.18B$25.58B$28.68B$31.37B+7.9%
Betriebsergebnis—$9.05B$9.63B$10.55B$11.97B+7.2%
Nettogewinn—$5.64B$5.24B$5.76B$6.78B+4.7%
EPS (verwässert)—$19.15$18.97$22.00$28.33+10.3%
EBITDA—$13.29B$12.72B$13.90B$15.60B+4.1%
F&E——————
VVG$26.78B$27.69B$29.49B$31.17B—+3.9%

Qualitäts-Scores

OCF / Nettogewinn
1.86×
>1 weist auf hohe Ergebnisqualität hin
Bilanzqualitätsschwelle
Fail
Sektoradjustierte Schwelle
ROIC
22.4%
Rendite auf eingesetztes Kapital
Abschnitt 3

Numbers analysis

Cashflow

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Kapitalallokation

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Einzelabonnenten — ab §411 weitere Abschnitte

Vollständige Analyse lesen — 11 weitere Abschnitte.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Vollständiger Bericht für jeden abgedeckten Ticker
24 Monate Rating-Archiv
Watchlist-Briefings + Rating-Änderungs-Warnungen
PDF + DOCX Export in jeder Sprache
Kostenlose Testversion starten
Jederzeit kündbar.
FAQ

HCA — frequently asked questions

  1. Based on our latest analysis, HCA looks meaningfully undervalued. The current price is $426 versus a composite fair-value midpoint of $647 (range $497–$798), which implies roughly 51.8% upside to the midpoint.

Related coverage

Names readers of HCA also follow

Same archetype: mature-compounder